

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

Listing of Claims

1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain approximately ~~12-17~~ 17 to 40 amino acids in length that binds to G-CSFR and contains a sequence of amino acids selected from the group consisting of GGGLLDICELKLOECARRCN (SEQ ID NO: 209); GRTGGLLDICEELKLOECARRCN (SEQ ID NO: 210); LGIEGRTGGLLDICEELKLOECARRCN (SEQ ID NO: 211); LLDICEELKLOEAARRCN (SEQ ID NO: 212); KLLDICEELKLOEAARRCN (SEQ ID NO: 213); and LLDICEELKLOECARRCN (SEQ ID NO: 214).

of formula (V) $(V) - C X_1^{IV} X_2^{IV} X_3^{IV} X_4^{IV} X_5^{IV} X_6^{IV} X_7^{IV} X_8^{IV} X_9^{IV} X_{10}^{IV} C$ (SEQ ID NO: 5) wherein each amino acid is indicated by standard one-letter abbreviation, and wherein X_1^{IV} is E, G, P, N, R, T, W, S, L, H, A, Q or Y; X_2^{IV} is S, T, E, A, D, G, W, P, L, N, V, Y, R or M; X_3^{IV} is R, Y, V, Q, E, T, L, P, S, K, M, A or W; X_4^{IV} is L, M, G, F, W, R, S, V, P, A, D, C or T; X_5^{IV} is V, T, A, R, S, L, W, C, I, E, P, H, F, D or Q; X_6^{IV} is E, Y, G, T, Q, M, S, N, A or P; X_7^{IV} is C, V, D, G, L, W, E, V, I, S, M or A; X_8^{IV} is S, Y, A, W, P, V, L, Q, G, K, F, I, E or D; X_9^{IV} is R, W, M, D, H, V, G, A, Q, L, S, E or Y; X_{10}^{IV} is M, L, I, S, V, P, W, F, T, Y, R, or Q; and wherein said compound does not comprise sequence LLDICEELKLOECARRCN (SEQ ID NO: 208).

163. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLOECARRCN (SEQ ID NO: 209).

X_1^{IV} is E; X_2^{IV} is S or A; X_3^{IV} is R; X_4^{IV} is L; X_5^{IV} is V or S; X_6^{IV} is E; X_7^{IV} is C; X_8^{IV} is S; X_9^{IV} is R; and X_{10}^{IV} is L.

164. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICEELKLOECARRCN (SEQ ID NO: 210).

the sequence of amino acids is selected from the group consisting of:

GGGLLDICELKLOECARRCN (SEQ ID NO: 209);


GRTGGLLDICEKLQECARRCN (SEQ ID NO: 210);

LGIEGRTGGGLLDICEKLQECARRC-N (SEQ ID NO: 211);

LLDICEELKLQEAARRCN (SEQ ID NO: 212); and

KLLDICEKLQEAARRCN (SEQ ID NO: 213).

165. (Currently amended) The compound of claim 162, comprising a dimer having the structure of formula (VIII)



wherein R^1 and R^2 are independently selected from the sequences of amino acids of claim 1; formula (V); βA is a β -alanine residue; $n1$, $n2$, $n3$, $n4$, x and y are independently zero or one with the proviso that the sum of x and y is either one or two; and Lk is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two-NH-linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Previously presented) The compound of claims 162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

170. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of any claim 162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.

175. (New) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211).

176. (New) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN (SEQ ID NO: 212).

177. (New) The compound of claim 162, wherein said sequence of amino acids is KLLDICEELKLQEAARRCN (SEQ ID NO: 213).

178. (New) The compound of claim 162, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343).